Epiminder (ASX:EPI): DETECT Study reaches 25th enrolment as US trial momentum builds

Epiminder (ASX:EPI), a medical device company developing continuous brain monitoring technology for epilepsy, has reached 25 patient enrolments in its DETECT US clinical study. DETECT is a prospective, randomised, controlled study supporting reimbursement for the Minder® System. Around 20 leading US sites are now active, including Mayo Clinic, Harvard, Stanford, Yale, Duke and the University of Pennsylvania, with enrolment accelerating as activation expands. CEO Rohan Hoare joins Lel Smits from The Stock Network to discuss what this patient enrolment milestone signals for trial execution, how site expansion is translating into recruitment, and the next key inflection points for investors.

1. Site expansion translating into enrolment growth
The study has reached 25 enrolled patients across more than 19 US sites, with recruitment accelerating alongside ongoing site activation. What is driving this momentum, and how should investors interpret early enrolment as an indicator of execution strength?

Take 2 start
2. Scaling toward critical trial thresholds
The study targets 210 patients across up to 25 US sites, with the next milestone of 50 patients expected in mid Q3 CY2026. How critical are the coming enrolment phases in validating clinical execution at scale?

3. Epiminder signal quality featured in publication
Epiminder was recently featured in another publication, can you talk us through the highlights?

4. Epiminder Director alignment
With four Epiminder Directors recently increasing their shareholdings in the company, what does this signal about internal confidence in the DETECT study progress and Epiminder's longer-term clinical and commercial outlook?

_ _ _

Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1
_ _ _

Follow TSN for the latest stock news and interviews:
Twitter: https://twitter.com/thestocknet
Instagram: https://www.instagram.com/thestocknetwork/
LinkedIn: https://www.linkedin.com/company/the-stock-network/
TikTok: https://www.tiktok.com/@thestocknet?lang=en
Facebook: https://www.facebook.com/TheStockNet/

_ _ _
Connect with our host Lel Smits online - @LelSmits
- Twitter / X: https://twitter.com/lelsmits
- Instagram: https://www.instagram.com/lelsmits/
- LinkedIn: https://www.linkedin.com/in/leldesmits/
- TikTok: https://www.tiktok.com/@lelsmits?lang=en
- Facebook: https://m.facebook.com/lelsmits/
- Threads: https://www.threads.net/@lelsmits
_ _ _

Disclaimer
The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss.

This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer.

_ _ _

Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au
_ _ _